title: Building a better therapy for stage IIIA non-small cell lung cancer.
abstract: What do clinicians know about stage IIIA lung cancer? They know accurate staging is critical and requires wide application of mediastinoscopy. They know that surgery and radiation alone each can cure a small subset of patients, and complete resection is of the utmost importance in surgically treated patients. They know that chemotherapy can increase the number of patients cured when combined with definitive radiation, and concurrent chemoradiotherapy seems superior to sequential. Neoadjuvant chemotherapy also seems to cure more patients than surgery alone, but more data are necessary. Trimodality therapy remains a promising but unproved approach in patients with stage IIIA disease. With the exciting new molecularly targeted agents, trials examining quad-modality therapy are just around the corner.
authors.affiliation: Dana-Farber/Partners Cancer Care, Harvard Medical School, Hematology/Oncology Unit, Massachusetts General Hospital, Boston, Massachusetts, USA. TEvans@Partners.org
authors.forename: Tracey L
authors.initials: TL
authors.lastname: Evans
authors.forename: Dean M
authors.initials: DM
authors.lastname: Donahue
authors.forename: Douglas J
authors.initials: DJ
authors.lastname: Mathisen
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Lynch
mesh_terms: D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy / Q000379:methods / Q000401:mortality; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000473:pathology* / Q000628:therapy*; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D011013:Pneumonectomy / Q000401:mortality; D016019:Survival Analysis